Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
106. |
ECCT/21/03/01 | Recombinant COVID-19 vaccine A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older |
Principal Investigator(s) 1. Walter Jaoko Jaoko Site(s) in Kenya KAVI-institute of Clinical Research |
View |
107. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
View |
108. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
View |
109. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
110. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
View |